Low-grade glioma (LGG, WHO grade 2 — IDH-mutant) · None
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Track | standard |
|---|---|
| Linked regimen | None |
| ID | IND-NF1-SUSPICION-PREVENTION-TESTING |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-19 | pending_clinical_signoff |
| Diseases | DIS-GLIOMA-LOW-GRADE |
| Sources | SRC-NCCN-BREAST-2025 SRC-NCCN-CNS-2025 SRC-NCCN-GENETIC-FAMILIAL-BREAST-OVARIAN-2025 |
Notes
STUB — v0.3 Wave M suspicion variant for NF1 hereditary prevention pilot. Pre-testing / pre-clinical-diagnosis pathway — patient transitions to RF-NF1-CONFIRMED-CARRIER / IND-NF1-CARRIER-PREVENTION-SURVEILLANCE upon positive germline test or NIH-criteria-met clinical diagnosis. Pediatric dimension important — clinical NF1 diagnosis may become evident in childhood without genetic testing.
Used By
No reverse references found in the YAML corpus.